Abstract:Purpose In this study, we aimed to investigate the viability of utilizing CytoSorter (R) system to detect circulating tumor cells (CTCs) and to evaluate the diagnostic value of CTCs in breast cancer (BC). Methods A total of 366 females patients suspected of having BC and 30 healthy female volunteers were enrolled in this study. CTCs were enriched by CytoSorter (R), a microfluidic-based CTCs capturing platform. CTC detection was performed before operation or biopsy. Based on the biopsy results, patients were divided into two groups, namely patients with BC and patients with benign breast diseases (BBD). Patients with BBD and healthy volunteers were serving as controls. The correlation between CTC enumeration and patients' clinicopathological characteristics was evaluated. The receiver operating characteristic (ROC) curve was plotted to assess the diagnostic potency of CytoSorter (R) system in BC. Results Based on the biopsy results, 130 BC patients at different cancer stages and 236 patients with BBD were enrolled in the study. Seven subjects were dropped out from the study. CTCs were detected in 109 of 128 BC patients, in one of 29 healthy volunteers, and in 37 of 232 patients with BBD. Maximum CTC counts detected in BC patients, healthy volunteers, and patients with BBD were 8, 1, and 4, respectively. Statistical analysis showed CTCs could be used to distinguish BC patients from healthy volunteers and patients with BBD (P < .0001). Circulating tumor cells were statistically associated with patients' cancer stage (P = .0126), tumor size (tumor node metastasis [TNM] T stage, P = .0253), cancer type (invasive vs noninvasive, P = .0141), and lymph node metastasis (P = .0436). More CTCs were found in patients at advanced cancer stage or TNM T stage and in patients with invasive tumor or lymph node metastasis. Furthermore, CTC detection rates in BC patients at Tis and T1-4 stages were 50%, 81.67%, 91.07%, 100%, and 100%, respectively. When the CTC cut-off value was set to 2, the ROC curve gave an area under the curve (AUC) of 0.86 with a specificity and sensitivity of 95.4% and 76.56%, respectively. Taken together, CTCs could be used as a diagnostic aid in assistance of cancer screening and staging. Conclusion Circulating tumor cells were successfully isolated in BC patients using CytoSorter (R) system. CTCs can be used to differentiate BC patients from the patients with BBD or healthy volunteers, and as a diagnostic aid for early cancer diagnosis and cancer staging.

A novel dual-function SERS-based identification strategy for preliminary screening and accurate diagnosis of circulating tumor cells

Evaluation of the Diagnostic Value of Circulating Tumor Cells with CytoSorter® CTC Capture System in Patients with Breast Cancer.

Machine Learning Assisted Dual-Modal SERS Detection for Circulating Tumor Cells

An efficient strategy for circulating tumor cell detection: surface-enhanced Raman spectroscopy

Efficient Detection of Single Circulating Tumor Cell in Blood Using Raman Mapping Based on Aptamer-SERS Bio-Probe Coupled with Micropore Membrane Filtration.

TiO2-based Surface-Enhanced Raman Scattering bio-probe for efficient circulating tumor cell detection on microfilter

Ultrahigh SERS activity of the TiO2@Ag nanostructure leveraged for accurately detecting CTCs in peripheral blood

A rapid and simple method for efficient capture and accurate discrimination of circulating tumor cells using aptamer conjugated magnetic beads and surface-enhanced Raman scattering imaging

PD-L1 Targeted Iron Oxide SERS Bioprobe for Accurately Detecting Circulating Tumor Cells and Delineating Tumor Boundary

Novel Nitrocellulose Membrane Substrate for Efficient Analysis of Circulating Tumor Cells Coupled with Surface-Enhanced Raman Scattering Imaging.

Precise diagnosis of tumor cells and hemocytes using ultrasensitive, stable, selective cuprous oxide composite SERS bioprobes assisted with high-efficiency separation microfluidic chips

Improved SERS Nanoparticles for Direct Detection of Circulating Tumor Cells in the Blood.

Octahedral Silver Oxide Nanoparticles Enabling Remarkable SERS Activity for Detecting Circulating Tumor Cells

Combination of Immunomagnetic Separation with Aptamer-Mediated Double Rolling Circle Amplification for Highly Sensitive Circulating Tumor Cell Detection

A Dual-Recognition-controlled Electrochemical Biosensor for Accurate and Sensitive Detection of Specific Circulating Tumor Cells.

Chip-Assisted Single-Cell Biomarker Profiling of Heterogeneous Circulating Tumor Cells Using Multifunctional Nanospheres

Multivalent Aptamer Functionalized Ag<sub>2</sub>S Nanodots/Hybrid Cell Membrane-Coated Magnetic Nanobioprobe for the Ultrasensitive Isolation and Detection of Circulating Tumor Cells

A Supersensitive CTC Analysis System Based on Triangular Silver Nanoprisms and SPION with Function of Capture, Enrichment, Detection, and Release

Combining Multiplex SERS Nanovectors and Multivariate Analysis for In Situ Profiling of Circulating Tumor Cell Phenotype Using a Microfluidic Chip.

Improved SERS-Active Nanoparticles with Various Shapes for CTC Detection Without Enrichment Process with Supersensitivity and High Specificity.

<strong>SERS-based single cell phenotype profiling on a microfluidic chip</strong>